



CannaKeys Launches Solution for Understanding the Science of Cannabis and the Endocannabinoid System

MONDAY, JANUARY 11TH, 2021

CannaKeys 360 aggregates the science of cannabis and the ECS with filterable, dashboard outputs to present a clear state of the science

Berkeley, CA. [CannaKeys](#), provider of platforms and services that help demystify the field of cannabinoid therapeutics, today announced the release of [CannaKeys 360](#), a solution developed to support healthcare providers, patients, policymakers, advocates, and the cannabis industry for understanding and applying the science of cannabis and the endocannabinoid system.

“Whether the question is a patient application, the assessment of qualifying conditions, or informing major policy decisions, the state of the science has been difficult to define and apply,” said Douglas Reil, Co-founder and CEO of CannaKeys, “With CannaKeys 360, a real-time summary of the state of the science for hundreds of conditions and more is available to all.”

CannaKeys 360 presents the science of the cannabis and endocannabinoid system aggregated for ease of use and designed to support healthcare decisions and improved patient outcomes. The dynamic platform currently offers over 2800 studies across 235+ medical conditions, accessible through four searches: medical condition, cannabinoid, terpene, and organ system. The search outputs are presented in easy-to-understand dashboards that present study lists, key findings, chemotype trends, clinical dosing, and other critical information. Results are fully filterable allowing quick access to just the information or trends needed, saving significant time in reviewing the available research.

“CannaKeys 360 is the answer to one of the biggest challenges in cannabis: finding quality research that supports cannabis medicine. The industry has needed a database that compiles and ranks cannabinoid research and CannaKeys 360 delivers just that. This will be a game changer for many of us who are seeking research to support our practice,” said Eloise Thiesen, RN, MSN, AGPCNP-BC, President, American Cannabis Nurses Association and Cofounder/Chief Visionary Officer, Radicle Health.

Defining the state of the science of cannabis has been elusive and the lack of clear information has kept both doctors and patients on the sidelines. With CannaKeys 360, the science-based decisions can be accelerated, engaging healthcare more broadly, giving patients more confidence with these therapies, and improving the consistency of patient care. Immediate access to aggregated science also supports the cannabis and terpene industries as well as driving policy change at local, state, and national levels worldwide.

“Reviewing the available science to identify what kind of cannabinoid-based therapeutics are thought to work for a particular condition can be a very time-consuming and laborious endeavor. The CannaKeys 360 platform is

designed to aggregate thousands of scientific studies to distill the relevant data to quickly make more informed, discerning, and evidence-based decisions,” said Uwe Blesching PhD, cofounder and Chief Science Officer of CannaKeys.

CannaKeys 360 is available by subscription for healthcare providers, patients, industry professionals, schools, and advocacy groups. To subscribe and learn more, visit cannakeys.com.

* * *

Contact: Douglas Reil
Email: doug@cannakeys.com

About CannaKeys

The mission of CannaKeys is to empower patients, medical professionals, caregivers, and the industry with the tools to maximize the effectiveness of cannabis therapeutics and create agency with regard to their applications. The company achieves that mission by creating platforms and services that support education on the cannabinoid health sciences and the effective and consistent use of these therapies.

Like us on Facebook: facebook.com/cannakeys/

Follow us on LinkedIn: linkedin.com/company/cannakeys/

See us on Instagram: instagram.com/cannakeys360/

